Atika Capital Management LLC Invests $3.64 Million in Guardant Health, Inc. $GH

Atika Capital Management LLC bought a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 85,500 shares of the company’s stock, valued at approximately $3,642,000. Atika Capital Management LLC owned about 0.07% of Guardant Health at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in GH. NewEdge Advisors LLC increased its holdings in Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after purchasing an additional 230 shares during the period. American Century Companies Inc. grew its holdings in Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after acquiring an additional 282 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Guardant Health by 0.9% in the 1st quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock valued at $2,177,000 after purchasing an additional 469 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Guardant Health by 25.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock valued at $112,000 after purchasing an additional 537 shares in the last quarter. Finally, GF Fund Management CO. LTD. lifted its position in shares of Guardant Health by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,164 shares of the company’s stock worth $135,000 after purchasing an additional 570 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Guardant Health stock opened at $58.50 on Thursday. The business has a 50 day simple moving average of $49.78 and a 200-day simple moving average of $45.78. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $60.68. The stock has a market capitalization of $7.30 billion, a PE ratio of -17.46 and a beta of 1.43.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. During the same period in the prior year, the firm posted ($0.84) earnings per share. The business’s quarterly revenue was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on GH. TD Securities lifted their price target on Guardant Health from $56.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, May 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 price target (up from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. Canaccord Genuity Group raised their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, May 1st. Raymond James Financial upped their target price on shares of Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, July 31st. Finally, Stifel Nicolaus upped their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. One analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of “Buy” and a consensus price target of $57.50.

Insider Activity at Guardant Health

In other news, Director Ian T. Clark sold 6,672 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the transaction, the director directly owned 9,851 shares of the company’s stock, valued at approximately $476,591.38. This represents a 40.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 3,337 shares of Guardant Health stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $47.22, for a total value of $157,573.14. Following the completion of the sale, the director owned 11,150 shares in the company, valued at approximately $526,503. This trade represents a 23.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 235,542 shares of company stock worth $11,852,491 in the last three months. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.